The 2014 European Drug Report package presents the most recent overview of the drug situation in Europe — published on 27 May
Registration now open for the Lisbon Addictions 2015 conference. Early bird fees available.
What are the trends and developments shaping the drug problem across Europe? Report available in 23 languages
Watch this video where our experts highlight the key issues in this year's European Drug Report
Read about the latest developments in the injection of synthetic cathinones
Explore the results of the largest European multi-city study on drug wastewater analysis
Learn about the latest developments in the cannabis market
We review the evidence for the treatment of cocaine dependence — are there effective medications available?
Internet-based drug treatment has expanded in Europe over the past 10 years — what is it and does it work?
Meeting with President of the European Parliament, Martin Schulz, 7 January 2015, Brussels
EMCDDA scientific paper award, 25 November 2014, Lisbon
International day against drug abuse and illicit trafficking, 26 June 2014
Launch of the European Drug Report, 27 June 2014
Note: photos will open in a new tab and are hosted on fickr.com.
Scientific paper award
Best practice portal
European Drug Report 2014
Note: videos will open in a new tab and are hosted on YouTube.com.
(30.01.2015) The speed with which the Internet is transforming drug markets poses a major challenge to law enforcement, public health, research and monitoring agencies. This is according to the latest ‘trendspotter’ study from the EMCDDA released today. Read more »
(27.01.2015) EMCDDA Director Wolfgang Götz is at the European Parliament today for an exchange of views with European members of the Global Commission on Drug Policy ahead of the United Nations General Assembly Special Session on drugs. Read more »
(21.01.2015) The EMCDDA Director is at the European Parliament today where he is presenting to members of the LIBE Committee highlights from the agency’s 2015 work programme and developments in the monitoring of new psychoactive substances. Read more »
(19.01.2015) Can naloxone provided in the community help reduce the thousands of drug-induced deaths recorded in Europe every year? Read more »
(15.01.2015) Registration opens today for the fourth European drugs summer school on ‘Illicit drugs in Europe: demand, supply and public policies’ (29 June to 10 July). Read more »
(08.12.2014) A new EMCDDA Paper explores how the economic recession has affected the financing of drug initiatives in Europe. Read more »
(01.12.2014) In Europe, decades of investment in effective HIV prevention measures targeting people who inject drugs continue to bear fruit. Read more »
(24.11.2014) The four winners of the EMCDDA scientific paper award 2014 will be honoured in Lisbon on 25 November at the fourth annual award ceremony hosted by the agency. Read more »
Drug profiles are scientifically sound descriptions of drugs
A synthetic substance, normally seen as a white powder, amphetamine acts as a stimulant of the central nervous system. Read more »
Barbiturates are synthetic substances manufactured as pharmaceutical products. They act as depressants of the central nervous system. Read more »
Benzodiazepines were introduced into medicine in 1961 and are widely used to treat anxiety and insomnia. Read more »
Despite some claims to the contrary, piperazine and its derivatives are synthetic substances that do not occur naturally. Read more »
Cannabis is one of the most widely consumed drugs throughout the world, and has been used since historical times. Read more »
Cocaine is a natural product extracted from the leaves of Erythroxylon coca Lam (coca leaves). Read more »
Fentanyl is a narcotic analgesic with a potency at least 80 times that of morphine used in both human and veterinary medicine. Read more »
‘Hallucinogenic mushrooms’ is the name commonly given to psychoactive fungi, containing hallucinogenic compounds. Read more »
Heroin is a crude preparation of diamorphine. It is a semisynthetic product obtained by acetylation of morphine. Read more »
Khat comprises the leaves and fresh shoots of a flowering evergreen shrub cultivated in East Africa and the S.W. Arabian Peninsula. Read more »
Mitragyna speciosa Korth. is a 4 to 16 metre high tropical tree. In Thailand, the tree and leaf-preparations from it are called kratom. Read more »
Lysergide (LSD) is a semi-synthetic hallucinogen, and is one of the most potent drugs known. Read more »
MDMA is a synthetic substance commonly known as ecstasy, although th latter term now covers a wide range of other substances. Read more »
A synthetic substance. Normally seen as a white powder, it acts as a stimulant of the central nervous system. Read more »
The psychoactive plant Salvia divinorum is a rare member of the mint family. Read more »
Synthetic cannabinoids are functionally similar to THC, the active principle of cannabis. Read more »
Synthetic cathinones are related to the parent compound cathinone, one of the psychoactive principals in khat. Read more »
A number of synthetic derivatives of cocaine have been investigated as potential pharmaceutical agent. Read more »
Domestic products such as spray deodorants, glue, lighter refills and spray air fresheners can be used as drugs. Read more »
European Drug Report 2014: Trends and developments
How many new drugs were detected in Europe over the last year? Is cannabis getting stronger? How many Europeans have ever used an illicit drug? What are the latest drug policy developments in the region? These are just some of the questions explored in the European Drug Report: Trends and developments.
EU drug markets report: a strategic analysis
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the markets for heroin, cocaine, cannabis, amphetamine, methamphetamine, ecstasy and new psychoactive substances.
Drug use, impaired driving and traffic accidents
This literature review provides a comprehensive report on the relationship between drug use, impaired driving and traffic accidents. It describes methodological issues, presents the results of studies and findings, and explores the relationship between drug use, driving impairment and traffic accidents.
New psychoactive substances in 2013
This report ('EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA') presents the key activities performed by the EMCDDA and Europol in 2013, including details on all the relevant activities on the information exchange, risk assessment and control of new psychoactive substances.
ECDC and EMCDDA guidance. Prevention and control of infectious diseases among people who inject drugs
This joint guidance report explores good public health practices that can support effective policies to reduce infections. HIV, hepatitis B and hepatitis C are mainly spread through the sharing of needles, syringes and drug preparation equipment or unprotected sexual contacts.
A year in review: Highlights from the EMCDDA’s General Report of Activities 2013
The series ‘A year in review’ contains the essence of the EMCDDA's General Report of Activities. It is designed to provide interested audiences with a brief, four-page summary of the agency’s achievements for the year concerned with a focus on key topics.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
The EMCDDA is located at:
Praça Europa 1, Cais do Sodré
Tel. (351) 211 21 02 00
More contact information >>
Page last updated: Friday, 30 January 2015